Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.

Marquis RW, Lago AM, Callahan JF, Rahman A, Dong X, Stroup GB, Hoffman S, Gowen M, DelMar EG, Van Wagenen BC, Logan S, Shimizu S, Fox J, Nemeth EF, Roethke T, Smith BR, Ward KW, Bhatnagar P.

J Med Chem. 2009 Nov 12;52(21):6599-605. doi: 10.1021/jm900563e.


An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation.

Kumar S, Matheny CJ, Hoffman SJ, Marquis RW, Schultz M, Liang X, Vasko JA, Stroup GB, Vaden VR, Haley H, Fox J, DelMar EG, Nemeth EF, Lago AM, Callahan JF, Bhatnagar P, Huffman WF, Gowen M, Yi B, Danoff TM, Fitzpatrick LA.

Bone. 2010 Feb;46(2):534-42. doi: 10.1016/j.bone.2009.09.028. Epub 2009 Sep 26.


Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys.

Stroup GB, Kumar S, Jerome CP.

Calcif Tissue Int. 2009 Oct;85(4):344-55. doi: 10.1007/s00223-009-9279-x. Epub 2009 Sep 10.


Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice.

Guo J, Bot I, de Nooijer R, Hoffman SJ, Stroup GB, Biessen EA, Benson GM, Groot PH, Van Eck M, Van Berkel TJ.

Cardiovasc Res. 2009 Feb 1;81(2):278-85. doi: 10.1093/cvr/cvn311. Epub 2008 Nov 17.


Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells.

Rickard DJ, Wang FL, Rodriguez-Rojas AM, Wu Z, Trice WJ, Hoffman SJ, Votta B, Stroup GB, Kumar S, Nuttall ME.

Bone. 2006 Dec;39(6):1361-72. Epub 2006 Aug 10.


Increased osteoblastogenesis and decreased bone resorption protect against ovariectomy-induced bone loss in thrombospondin-2-null mice.

Hankenson KD, James IE, Apone S, Stroup GB, Blake SM, Liang X, Lark MW, Bornstein P.

Matrix Biol. 2005 Aug;24(5):362-70.


Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics.

Potter LK, Greller LD, Cho CR, Nuttall ME, Stroup GB, Suva LJ, Tobin FL.

Bone. 2005 Aug;37(2):159-69.


An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey.

Marquis RW, Ward KW, Roethke T, Smith BR, Ru Y, Yamashita DS, Tomaszek TA, Gorycki PD, Cheng HY, James IE, Stroup GB, Lark MW, Gowen M, Veber DF.

Mol Pharm. 2004 Jan 12;1(1):97-100. No abstract available.


A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, Lechowska BA, Hoffman SJ, Smith BR, Kapadia R, Liang X, Erhard K, Ru Y, Dong X, Marquis RW, Veber D, Gowen M.

Bone. 2002 May;30(5):746-53.


Reduction in animal numbers by long-term implantation of intravenous and intra-arterial catheters in thyroparathyroidectomized rats.

Lechowska BA, Bhattacharyya A, Vasko-Moser J, Stroup GB.

Comp Med. 2001 Dec;51(6):518-23.


Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.

Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M.

J Bone Miner Res. 2001 Oct;16(10):1739-46.


Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis.

Badger AM, Blake S, Kapadia R, Sarkar S, Levin J, Swift BA, Hoffman SJ, Stroup GB, Miller WH, Gowen M, Lark MW.

Arthritis Rheum. 2001 Jan;44(1):128-37.


Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat.

Lark MW, Stroup GB, Dodds RA, Kapadia R, Hoffman SJ, Hwang SM, James IE, Lechowska B, Liang X, Rieman DJ, Salyers KL, Ward K, Smith BR, Miller WH, Huffman WF, Gowen M.

J Bone Miner Res. 2001 Feb;16(2):319-27.


Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.

Nuttall ME, Stroup GB, Fisher PW, Nadeau DP, Gowen M, Suva LJ.

Am J Physiol Cell Physiol. 2000 Nov;279(5):C1550-7.


Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.

Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J.

J Clin Invest. 2000 Jun;105(11):1595-604.


Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, Rieman DJ, Gowen M, Boehm JC, Adams JL, Lee JC.

Arthritis Rheum. 2000 Jan;43(1):175-83.


Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.

Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan CC, Haltiwanger RC, Gowen M, Hwang SM, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF.

J Med Chem. 2000 Jan 13;43(1):22-6. No abstract available.


Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis.

Badger AM, Blake SM, Dodds RA, Griswold DE, Swift BA, Rieman DJ, Stroup GB, Hoffman SJ, Gowen M.

J Pharmacol Exp Ther. 1999 Dec;291(3):1380-6.


Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

Lark MW, Stroup GB, Hwang SM, James IE, Rieman DJ, Drake FH, Bradbeer JN, Mathur A, Erhard KF, Newlander KA, Ross ST, Salyers KL, Smith BR, Miller WH, Huffman WF, Gowen M.

J Pharmacol Exp Ther. 1999 Nov;291(2):612-7.


Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

Miller WH, Bondinell WE, Cousins RD, Erhard KF, Jakas DR, Keenan RM, Ku TW, Newlander KA, Ross ST, Haltiwanger RC, Bradbeer J, Drake FH, Gowen M, Hoffman SJ, Hwang SM, James IE, Lark MW, Lechowska B, Rieman DJ, Stroup GB, Vasko-Moser JA, Zembryki DL, Azzarano LM, Adams PC, Huffman WF, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.


Applications of micro-CT and MR microscopy to study pre-clinical models of osteoporosis and osteoarthritis.

Kapadia RD, Stroup GB, Badger AM, Koller B, Levin JM, Coatney RW, Dodds RA, Liang X, Lark MW, Gowen M.

Technol Health Care. 1998 Dec;6(5-6):361-72.


Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.

Nuttall ME, Bradbeer JN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H, Rehm S, Gowen M.

Endocrinology. 1998 Dec;139(12):5224-34.


Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements.

Bradbeer JN, Kapadia RD, Sarkar SK, Zhao H, Stroup GB, Swift BA, Rieman DJ, Badger AM.

Arthritis Rheum. 1996 Mar;39(3):504-14.


Identification and characterization of two distinct alpha-(1-3)-L-fucosyltransferase activities in human colon carcinoma.

Stroup GB, Anumula KR, Kline TF, Caltabiano MM.

Cancer Res. 1990 Nov 1;50(21):6787-92.

Supplemental Content

Loading ...
Support Center